YC-1 targeting of hypoxia-inducible factor-1α reduces RGC-5 cell viability and inhibits cell proliferation

Leo Tsui, Tsorng Harn Fong, I. Jong Wang

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Purpose: The survival of retinal ganglion cells (RGCs) is a hallmark of many optic neurodegenerative diseases such as glaucoma. YC-1, a potential anticancer drug, is known to be able to decrease the stability and protein expression of hypoxiainducible factor (HIF)-1α that is triggered by hypoxia and related to RGC survival. We hypothesized that YC-1 may alter RGC cell viability through the down-regulation of HIF-1α. Methods: Cell viability of the RGC-5 cell line was measured with a 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. Flow cytometry, a LIVE/DEAD viability assay, and high-content screening (HCS) with MKI67 (K i-67) monoclonal antibodies were used to detect cell death and cellular proliferation. Results: We found that cells treated with 20 μM YC-1 for 24 h decreased the HIF-1α level in an RGC-5 cell line using immunoblotting and reduced the live cell number in an MTT assay. Results of flow cytometry and HCS demonstrated that reducing the cell proliferation of RGC-5 cells, not cell death, led to the decreased level in the MTT assay. Conclusions: Our findings demonstrate that YC-1-induced down-regulation of HIF-1α might reduce RGC cell proliferation and viability under normoxia, which implies a role of YC-1 in the neuroprotective effect for further clinical applications.

Original languageEnglish
Pages (from-to)1594-1603
Number of pages10
JournalMolecular Vision
Volume18
Publication statusPublished - Jun 15 2012

Fingerprint

Hypoxia-Inducible Factor 1
Retinal Ganglion Cells
Cell Survival
Cell Proliferation
Flow Cytometry
Cell Death
Down-Regulation
Cell Line
Protein Stability
Neuroprotective Agents
Immunoblotting
Neurodegenerative Diseases
Glaucoma
Cell Count
Monoclonal Antibodies
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Ophthalmology

Cite this

YC-1 targeting of hypoxia-inducible factor-1α reduces RGC-5 cell viability and inhibits cell proliferation. / Tsui, Leo; Fong, Tsorng Harn; Wang, I. Jong.

In: Molecular Vision, Vol. 18, 15.06.2012, p. 1594-1603.

Research output: Contribution to journalArticle

@article{c13a57369b4349cd9fad90ee8143a202,
title = "YC-1 targeting of hypoxia-inducible factor-1α reduces RGC-5 cell viability and inhibits cell proliferation",
abstract = "Purpose: The survival of retinal ganglion cells (RGCs) is a hallmark of many optic neurodegenerative diseases such as glaucoma. YC-1, a potential anticancer drug, is known to be able to decrease the stability and protein expression of hypoxiainducible factor (HIF)-1α that is triggered by hypoxia and related to RGC survival. We hypothesized that YC-1 may alter RGC cell viability through the down-regulation of HIF-1α. Methods: Cell viability of the RGC-5 cell line was measured with a 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. Flow cytometry, a LIVE/DEAD viability assay, and high-content screening (HCS) with MKI67 (K i-67) monoclonal antibodies were used to detect cell death and cellular proliferation. Results: We found that cells treated with 20 μM YC-1 for 24 h decreased the HIF-1α level in an RGC-5 cell line using immunoblotting and reduced the live cell number in an MTT assay. Results of flow cytometry and HCS demonstrated that reducing the cell proliferation of RGC-5 cells, not cell death, led to the decreased level in the MTT assay. Conclusions: Our findings demonstrate that YC-1-induced down-regulation of HIF-1α might reduce RGC cell proliferation and viability under normoxia, which implies a role of YC-1 in the neuroprotective effect for further clinical applications.",
author = "Leo Tsui and Fong, {Tsorng Harn} and Wang, {I. Jong}",
year = "2012",
month = "6",
day = "15",
language = "English",
volume = "18",
pages = "1594--1603",
journal = "Molecular Vision",
issn = "1090-0535",

}

TY - JOUR

T1 - YC-1 targeting of hypoxia-inducible factor-1α reduces RGC-5 cell viability and inhibits cell proliferation

AU - Tsui, Leo

AU - Fong, Tsorng Harn

AU - Wang, I. Jong

PY - 2012/6/15

Y1 - 2012/6/15

N2 - Purpose: The survival of retinal ganglion cells (RGCs) is a hallmark of many optic neurodegenerative diseases such as glaucoma. YC-1, a potential anticancer drug, is known to be able to decrease the stability and protein expression of hypoxiainducible factor (HIF)-1α that is triggered by hypoxia and related to RGC survival. We hypothesized that YC-1 may alter RGC cell viability through the down-regulation of HIF-1α. Methods: Cell viability of the RGC-5 cell line was measured with a 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. Flow cytometry, a LIVE/DEAD viability assay, and high-content screening (HCS) with MKI67 (K i-67) monoclonal antibodies were used to detect cell death and cellular proliferation. Results: We found that cells treated with 20 μM YC-1 for 24 h decreased the HIF-1α level in an RGC-5 cell line using immunoblotting and reduced the live cell number in an MTT assay. Results of flow cytometry and HCS demonstrated that reducing the cell proliferation of RGC-5 cells, not cell death, led to the decreased level in the MTT assay. Conclusions: Our findings demonstrate that YC-1-induced down-regulation of HIF-1α might reduce RGC cell proliferation and viability under normoxia, which implies a role of YC-1 in the neuroprotective effect for further clinical applications.

AB - Purpose: The survival of retinal ganglion cells (RGCs) is a hallmark of many optic neurodegenerative diseases such as glaucoma. YC-1, a potential anticancer drug, is known to be able to decrease the stability and protein expression of hypoxiainducible factor (HIF)-1α that is triggered by hypoxia and related to RGC survival. We hypothesized that YC-1 may alter RGC cell viability through the down-regulation of HIF-1α. Methods: Cell viability of the RGC-5 cell line was measured with a 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. Flow cytometry, a LIVE/DEAD viability assay, and high-content screening (HCS) with MKI67 (K i-67) monoclonal antibodies were used to detect cell death and cellular proliferation. Results: We found that cells treated with 20 μM YC-1 for 24 h decreased the HIF-1α level in an RGC-5 cell line using immunoblotting and reduced the live cell number in an MTT assay. Results of flow cytometry and HCS demonstrated that reducing the cell proliferation of RGC-5 cells, not cell death, led to the decreased level in the MTT assay. Conclusions: Our findings demonstrate that YC-1-induced down-regulation of HIF-1α might reduce RGC cell proliferation and viability under normoxia, which implies a role of YC-1 in the neuroprotective effect for further clinical applications.

UR - http://www.scopus.com/inward/record.url?scp=84863322445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863322445&partnerID=8YFLogxK

M3 - Article

VL - 18

SP - 1594

EP - 1603

JO - Molecular Vision

JF - Molecular Vision

SN - 1090-0535

ER -